# Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis

> **NCT01509339** · PHASE1 · WITHDRAWN · sponsor: **Case Western Reserve University**

## Conditions studied

- Cystic Fibrosis
- Methicillin-resistant Staphylococcus Aureus

## Interventions

- **DRUG:** Vancomycin

## Key facts

- **NCT ID:** NCT01509339
- **Lead sponsor:** Case Western Reserve University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-01
- **Primary completion:** 2021-12-23
- **Final completion:** 2021-12-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lab unable to measure vancomycin levels in Sputum
- **Last updated:** 2022-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01509339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01509339, "Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01509339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*